Wound Healing Society Acknowledges Eluciderm, Inc. with Industrial R&D Award for Advancing ELU42 Mechanism of Action Research Eluciderm, Inc., a clinical-stage biopharmaceutical organization focused on the development of innovative small-molecule…
Annals of Internal Medicine Reports One-Year Findings from LivaNova’s OSPREY Clinical Trial in Obstructive Sleep Apnea LivaNova PLC (Nasdaq: LIVN) has announced the publication of comprehensive 12-month results from its…
Entos Pharmaceuticals and L-CMD Research Foundation Join Forces to Develop Curative Therapy for LMNA-Related Congenital Muscular Dystrophy Entos Pharmaceuticals Inc has announced a strategic collaboration with the L-CMD Research Foundation…
Speak Foundation Introduces Patient-Led National LGMD Centers of Excellence to Drive Clinical Trials and Innovative Treatments Speak Foundation has announced the launch of a major new initiative aimed at transforming…
Dana-Farber Study Shows Predictive Potential of Ignite Proteomics’ RPPA Platform for Enhertu® (T-DXd) in Metastatic Breast Cancer Aditxt Inc. has announced a notable scientific and clinical milestone involving its precision…
Palleon Pharmaceuticals Showcases First-in-Class B7-H3–Targeted Sialidase at AACR 2026 Palleon Pharmaceuticals has unveiled new preclinical findings and announced the initiation of a first-in-human clinical trial for its novel oncology candidate…
Neurogene Announces Christy Shafer as Chief Commercial Officer and Appoints Christine Mikail, J.D., to Its Board Neurogene Inc. has announced key leadership additions as it advances its mission to develop…
Pulse Biosciences Highlights nPulse™ Technology Presentation at Heart Rhythm Society 2026 Annual Meeting Pulse Biosciences has announced a strong presence at the upcoming Heart Rhythm Society Annual Meeting, where it…
Bicycle Therapeutics Shares Pipeline Update on Nuzefatide Pevedotin and EphA2 Programs at AACR 2026 Bicycle Therapeutics has unveiled a comprehensive set of updates from its EphA2-targeting oncology pipeline at the…
RareCyte Broadens Clinical-Scale Spatial Proteomics Offering with New Orion Systems and Leadership Addition RareCyte has announced a major expansion of its spatial proteomics capabilities, marking a strategic step forward in…
FDA Prioritizes Review of KEYTRUDA® and KEYTRUDA QLEX™ Combinations with Padcev® for Cisplatin-Eligible Muscle-Invasive Bladder Cancer Patients Merck & Co., known as MSD outside the United States and Canada, has…
Synthetic Design Lab reveals first logic-gated ADC at AACR 2026 with ≥10x enhanced targeted cancer cell killing Synthetic Design Lab, an emerging innovator in the field of antibody-drug conjugates (ADCs)…